Magnetic resonance elastography (MRE) and transient elastography (TE) are noninvasive techniques used to detect liver fibrosis in nonalcoholic fatty liver disease. MRE detects fibrosis more accurately than TE, but MRE is more expensive, and the concordance between MRE and TE have not been optimally assessed in obese patients. It is important to determine under which conditions TE and MRE produce the same readings, so that some patients can simply undergo TE evaluation to detect fibrosis. We aimed to assess the association between body mass index (BMI) and discordancy between MRE and TE findings, using liver biopsy as the reference, and validated our findings in a separate cohort.
N onalcoholic fatty liver disease (NAFLD) is currently one of the most prevalent causes of chronic liver disease worldwide and is estimated to affect approximately one-third of the adult population in the United States. 1 Recent studies have suggested that presence of liver fibrosis, especially significant liver fibrosis (stage !2), portends a worse prognosis in NAFLD [2] [3] [4] and that long-term liver-related events increase with increase in fibrosis stage. 4 Therefore, the detection of significant liver fibrosis is important and clinically relevant for the management of patients with NAFLD. 4 Transient elastography (TE; FibroScan, Echosens, Paris, France) allows rapid, bed-side liver stiffness measurements (LSM). TE has been shown to correlate with stage of fibrosis, particularly in severe fibrosis and cirrhosis. 5, 6 Although the use of conventional M probe is limited by a high technical failure rate in individuals with body mass index (BMI) >28 kg/m 2 , the use of XL probe has shown to reduce the failure rate for measuring fibrosis in obese patients. [7] [8] [9] However, magnetic resonance elastography (MRE) has been demonstrated to accurately diagnose fibrosis in patients with NAFLD 10, 11 and to be accurate and effective in patients with obesity. 9, 12, 13 However, a magnetic resonance imaging-based technique, such as MRE, is often regarded as more expensive than an ultrasound-based technique, such as TE.
The optimal clinical approach for noninvasive detection of liver fibrosis in NAFLD remains unclear especially in patients with higher BMI. 14 Studies have demonstrated that MRE is more accurate than TE for the diagnosis of liver fibrosis in patients with NAFLD, 15, 16 but the key unmet need in the field is to assess when TE gives the same reading as MRE so that in the future clinicians do not need to perform MRE in those patients where TE provides similar degree of accuracy for the detection of fibrosis. Therefore, we conducted a cross-sectional analysis in a training cohort and a validation cohort to fill this gap in knowledge.
Using a well-characterized, prospective cohort of American adults with suspected NAFLD derived from the University of California at San Diego (UCSD) NAFLD Cohort, who underwent contemporaneously a liver biopsy and MRE and TE measurement with M and XL probes, we aimed to assess the association between BMI and the discordancy between MRE and TE for the stage of fibrosis (2-4 vs 0-1) using liver biopsy as the gold standard. We then validated our findings using an independent validation cohort including 75 prospectively recruited obese patients with biopsy-proven NAFLD derived from the Mayo Clinic NAFLD Cohort.
Materials and Methods

Study Participant and Design in University of California at San Diego Training Cohort
This study included consecutively a training cohort derived from a cross-sectional analysis of a prospective UCSD NAFLD Cohort of 119 adults with suspected NAFLD who underwent contemporaneous MRE, TE, and liver biopsy from October 2011 through January 2017. All patients with suspected NAFLD with a clinical indication for liver biopsy underwent a careful evaluation for other causes of hepatic steatosis and liver disease. Informed written consent was obtained from all patients and this study was approved by the UCSD Institutional Review Board and the Clinical and Translational Research Institute.
Inclusion/Exclusion Criteria for the University of California at San Diego Nonalcoholic Fatty Liver Disease Cohort
Participants were included in the study if they were 18 years or older with suspected NAFLD and were willing and able to provide informed consent. The Supplementary Material provides detailed exclusion criteria.
Histologic Evaluation in University of California at San Diego Nonalcoholic Fatty Liver Disease Cohort
All liver biopsies were performed by an experienced liver pathologist who was blinded to the patient's clinical and radiologic data. The NASH-CRN Histologic Scoring System 17 was used to assess liver fibrosis classified into 5 stages (0-4). The Supplementary Material provides additional details.
Magnetic Resonance Elastography in University of California at San Diego Nonalcoholic Fatty Liver Disease Cohort
MRE was performed at the UCSD MR3T Research Laboratory using the 3-T research scanner (GE Signa EXCITE HDxt, GE Healthcare, Waukesha, WI) and is fully detailed in the Supplementary Material.
Transient Elastography in University of California at San Diego Nonalcoholic Fatty Liver Disease Cohort
TE was performed by a trained technician, blinded to clinical and histologic results, using the FibroScan 502 Touch model (Echosens). Detailed methods have been previously described 16 and are detailed in the Supplementary Material.
Mayo Clinic Nonalcoholic Fatty Liver Disease Validation Cohort
The Mayo Clinic NAFLD cohort included 75 adults with NAFLD who underwent contemporaneous MRE, TE, and liver biopsy from March 2010 through May 2013. Informed written consent was obtained from all patients and this Health Insurance Portability and Accountability Act-compliant study was approved by the Mayo Clinic Institutional Review Board. The data were retrieved from a previously published study 9 and the data extraction flow-chart is provided in Supplementary Figure 1 .
Inclusion/Exclusion Criteria for the Mayo Clinic Nonalcoholic Fatty Liver Disease Cohort
Participants were included in the study if they were 18 years or older with NAFLD verified with liver histologic examination within at least 48 hours, but no later than 1 month, of study enrollment and were willing and able to provide informed consent. The Supplementary material provides detailed exclusion criteria.
Histologic Evaluation of Mayo Clinic Nonalcoholic Fatty Liver Disease Cohort
Liver biopsy was performed by using either a percutaneous needle biopsy or subcapsular wedge biopsy as per standard of care. The Brunt classification was used to assess liver fibrosis classified into 5 stages (0-4). The Supplementary Material provides additional details.
Magnetic Resonance Elastography of Mayo Clinic Nonalcoholic Fatty Liver Disease Cohort
MRE were performed at the Mayo Clinic using a 1.5-T whole-body magnetic resonance imaging unit with a 60-cm bore (Signa, GE Medical Systems, Milwaukee, WI) with all participants in the supine position. The Supplementary Material provides additional details.
Transient Elastography of Mayo Clinic Nonalcoholic Fatty Liver Disease Cohort
TE was performed by a trained technician, blinded to clinical and histologic results, using the FibroScan (Echosens). The Supplementary Material provides additional details.
Outcome Measures
MRE and TE were considered in concordance for the stage of fibrosis if they both correctly staged the fibrosis according to liver biopsy assessment. Thus, the concordance-rate was defined by individuals with concordant MRE and TE for the stage of fibrosis using liver biopsy as gold standard. The discordance-rate was defined by default as all nonconcordant individuals.
The primary outcome was discordance-rate between MRE and TE for the stage of significant fibrosis (stage 2-4 vs 0-1) using the liver biopsy as the gold standard. Secondary outcomes was the discordance-rate between MRE and TE for the stage of dichotomized stage of fibrosis (1-4 vs 0, 3-4 vs 0-2, and 4 vs 0-3) using the liver biopsy as the gold standard.
Statistical Analyses
Patients' demographic data, laboratory, and imaging data were summarized with mean and standard deviation for continuous variables and with numbers and percentages for categorical variables. Mean and frequency were compared using an independent samples Student t test or Wilcoxon rank sum test or chi-square test or Fisher exact test, where appropriate. Unreliable measurements was defined as success rate <60% and/ or number of valid measurement <10 and/or interquartile range/median LSM >30%. 18 The unreliable LSM were classified in the discordant group because the study aimed at assessing when TE gives the same reading as MRE so that there is no need to perform MRE in those patients in future. Thus, unreliable LSM needed to be considered and the analysis was performed in intention to diagnose.
The thresholds of MRE and TE used for the dichotomized stage of liver fibrosis were previously determined in each cohort, respectively 9, 16 : the threshold used for classification of liver fibrosis stage 2-4 versus 0-1 using TE were 7.80 kPa and 6.90 kPa; and using MRE were 3.50 kPa and 2.86 kPa in the Mayo Clinic NAFLD Cohort and UCSD NAFLD Cohort, respectively.
The odds ratios (OR) were determined using univariate and multiadjusted logistic regression. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC) or SPSS (IBM, Chicago, IL). A 2-tailed P value <.05 was considered statistically significant.
Results
Baseline Characteristics of University of California at San Diego Nonalcoholic Fatty Liver Disease Cohort
The training cohort included 119 individuals (54.6% female) with mean (AE standard deviation) age and BMI of 49.8 (AE 14.5) years and 30.6 (AE 5.1) kg/m 2 , respectively. The 119 TE were performed using either M probe (n ¼ 66; 55.5%) or XL probe (n ¼ 53; 44.5%) when appropriate. The discordance-rate between MRE and TE using liver biopsy as the gold standard for the stage of significant liver fibrosis (2-4 vs 0-1) was 43.7% (n ¼ 52) ( Figure 1A ). The type of discordancy is provided in Supplementary Figure 3A . Baseline characteristics are summarized in Table 1 . , respectively. The discordance-rate between MRE and TE for the diagnosis of liver fibrosis (2-4 vs 0-1) was 45.3% (n ¼ 34) ( Figure 1B ). The type of discordancy is provided in Supplementary  Figure 3B . Baseline characteristics are summarized in Table 2 . The distribution of the MRE and TE measurements among the concordant and discordant group in both cohorts is represented in Supplementary Figure 2 .
Body Mass Index is a Predictor of Discordancy Between Magnetic Resonance Elastography and Transient Elastography for the Stage of Fibrosis
The BMI was a significant predictor of discordancy between MRE and TE for the stage of significant liver fibrosis (2-4 vs 0-1) in the univariate analysis with an OR of 1.626 (95% confidence interval [CI], 1.116-2.370; P ¼ .0113) in the UCSD NAFLD Cohort (Table 3 ). After multivariable adjustment by age and sex, the BMI remained a significant predictor of discordancy between MRE and TE for the stage of significant liver fibrosis with an OR for 5-unit increase of 1.694 (95% CI, 1.145-2.507; P ¼ .008). The discordance-rate between MRE and TE increased along with the increase in BMI (P for trend ¼ .0309) (Figure 2A ). In addition, the discordance-rate between MRE and TE for the diagnosis of fibrosis was significantly higher in participants with BMI !35 kg/m 2 compared with participants with BMI <35 kg/m 2 (63.0% vs 38.0%; P ¼ .022) in the UCSD NAFLD Cohort ( Figure 3A) . The distribution of the BMI across the discordant and concordant group is provided in Supplementary Figure 4A .
The association between the BMI and the discordancy between MRE and TE for the stage of significant liver fibrosis was then validated in the Mayo Clinic NAFLD Cohort, which included mainly obese individuals. The BMI was a significant predictor of discordancy between MRE and TE for the stage of significant liver fibrosis in the univariate analysis with an OR of 1.469 (95% CI, 1.019-2.116; P ¼ .0391) ( Table 3) . After multivariableadjustment by age and sex, the BMI remained a significant predictor of discordancy between MRE and TE with an OR for 5-unit increase of 1.520 (95% CI, 1.044-2.213; P ¼ .029). As observed in the UCSD NAFLD Cohort, the discordance-rate between MRE and TE increased along with the increased in BMI (P for trend ¼ .0011) in the Mayo Clinic NAFLD Cohort ( Figure 2B ). In addition, the discordance-rate between MRE and TE for the stage of fibrosis was significantly higher in morbid obese individuals compared with nonmorbid obese individuals (66.0% vs 35.7%; P ¼ .001) ( Figure 3B ). The distribution of the BMI across the discordant and concordant group is provided in Supplementary Figure 4B .
Sensitivity Analyses
We conducted sensitivity analysis to further assess if the type of probe used for TE assessment influenced the impact of obesity for the discordancy between MRE and TE. The distribution of M and XL probe used for TE assessment was not significantly different across the concordant and discordant group in both UCSD NAFLD Cohort and the Mayo Clinic NAFLD Cohort (Supplementary Table 1 ).
Discussion
Main Findings
Using 2 independent prospective cohorts of wellcharacterized patients with biopsy-proven NAFLD, this study demonstrates the BMI is a significant factor of discordancy between MRE and TE for the stage of significant fibrosis (2-4 vs 0-1). Furthermore, this study showed that the grade of obesity is also a significant predictor of discordancy between MRE and TE because the discordance-rate between MRE and TE increases with the increase in BMI. In the context of the high prevalence of obesity in NAFLD, these results have important implications in developing an optimal clinical approach for noninvasive screening of liver fibrosis in NAFLD. Further cost-effectiveness studies are needed to determine the optimal approach for the detection of liver fibrosis taking into account the higher risk of liver fibrosis and the higher discordance-rate when the BMI increases.
In Context With Published Literature
The detection of significant liver fibrosis (!2) is an important feature of NAFLD because significant stage of 15 have shown that MRE is more accurate than TE for diagnosing significant fibrosis and cirrhosis in a Japanese cohort (mean BMI, 28.1 kg/m 2 ). In the USCD Cohort including participants with higher BMI (mean, 30.4 kg/m
2 ), we have demonstrated that MRE is more accurate than TE for diagnosing any fibrosis. 16 Finally, in the Mayo Clinic Cohort including severe obese adults with liver disease caused mainly by NAFLD, the accuracy of MRE was higher than TE for diagnosing significant fibrosis and advanced fibrosis. 9 Given the different range of BMI across these 3 studies, the association between BMI and the discordancy between TE and MRE could not have been fully assessed. This study provides evidence that the BMI is a significant predictor of discordancy between MRE and TE in 2 independent cohorts encompassing a large range of BMI and using M or XL probes for TE assessment when appropriate.
Severe obesity is associated with a higher skin-tocapsule distance, which is a major cause of unreliable LSM using standard M probes. The use of the XL probes generating a lower frequency reduces the failure rate of LSM in obese patients. 7, 8 Despite the use of XL probe when appropriate, our study demonstrates that the discordancy between MRE and TE increases with increase of the BMI. Although, the skin-to-capsule distance was not measured in our study, these results suggest that the lower ultrasound frequency generated by the XL probe may not be sufficient to accurately assess LSM when the skin-to-capsule distance increases especially when the BMI is higher than 35 kg/m 2 . In addition, the optimum positioning of the probe in individuals with severe obesity may be more difficult and less reproducible. Hence, the variability and interquartile range of the LSM may significantly increase when the BMI increases. 19 Although TE has excellent interoperator and intraoperator reproducibility in nonobese populations, 20 there are no data regarding the sampling variability and interobserver variability in NAFLD populations with higher BMI. In addition, XL probe tends to generate lower LSM than M probe in the same patient, which suggests the need to define specific cutoffs depending on the type of probe used. 7, 8 Finally, TE assesses a limited spot of the liver measured, whereas MRE includes a larger area, which may reduce sampling variability because of heterogeneity of liver fibrosis.
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Strengths and Limitations
There are several notable strengths of this study including a training cohort and a validation cohort, both prospectively recruited and well-characterized by experienced investigators at dedicated research centers specialized for clinical and radiologic research. All participants of the training cohort derived from the UCSD NAFLD Cohort, underwent a systematic and standardized liver disease assessment to exclude for other causes of liver disease before inclusion in the study and the liver biopsy, used as the reference standard for imaging, was scored using the well-validated NASH-CRN Histologic Scoring System. Although the liver biopsies were assessed using the Brunt classification in the Mayo Clinic, the scoring for the stage of fibrosis is similar in these 2 methods and thus can be compared. Although the liver biopsy accuracy has been questioned because of sampling errors and variable intraobserver and interobserver agreement, 21, 22 it remains the gold standard for assessing liver fibrosis and thus we used the liver biopsy as reference in our study. However, we acknowledge following limitations of this study. This study was conducted at highly specialized tertiary care centers using advanced magnetic resonance imaging techniques that may not be available in other clinical centers. Thus the generalizability of these findings in other clinical settings is unknown. In addition, both cohorts included a relative small proportion of individuals with advanced fibrosis (stage 3-4) and spectrum variability cannot be excluded. However, the UCSD cohort has consecutively enrolled patients with suspected NAFLD indicated for a liver biopsy and the proportion of individuals with advanced fibrosis of the cohort reflects the spectrum of the disease. Therefore the results of the study are unlikely to be biased by the fibrosis stage distribution. Finally, we applied the optimum thresholds of TE and MRE for the detection of fibrosis stage defined in each cohort to limit potential bias. Indeed, there are no validated thresholds for the stage of fibrosis in a large NAFLD cohort and further studies are needed to determine optimum thresholds of MRE and TE using M and XL probe in NAFLD.
Implications for Clinical Care and Future Research
This study provides important insight for the management of patients with NAFLD in routine clinical practice. The integration of the BMI in the screening strategy for the noninvasive detection of liver fibrosis in NAFLD should be considered and this parameter would help to determine when MRE is not needed in future guidelines. Further cost-effectiveness studies are necessary to evaluate the clinical utility of MRE, TE, and/or liver biopsy to develop optimal screening strategies for diagnosing NAFLD-associated fibrosis. 
University of California at San Diego Nonalcoholic Fatty Liver Disease Cohort
Inclusion/Exclusion Criteria for the University of California at San Diego Nonalcoholic Fatty Liver Disease Cohort. Participants were included in the study if they were 18 years or older with suspected nonalcoholic fatty liver disease (NAFLD) and were willing and able to provide informed consent.
Participants were excluded if they met any of the following criteria: history of regular and excessive alcohol consumption within 2 years of recruitment (!14 drinks/week for men or !7 drinks/week for women); use of hepatotoxic drugs or drugs known to cause hepatic steatosis; any evidence of secondary causes of hepatic steatosis, including viral hepatitis (detected with positive serum hepatitis B surface antigen or hepatitis C viral RNA), Wilson disease, hemochromatosis, a 1 -antitrypsin deficiency, autoimmune hepatitis, and cholestatic or vascular liver disease; evidence of decompensated liver disease (defined as Child-Pugh score >7 points); clinical or laboratory evidence of chronic illnesses associated with hepatic steatosis, including human immunodeficiency virus infection, type 1 diabetes mellitus, celiac disease, cystic fibrosis, lipodystrophy, dysbetalipoproteinemia, and glycogen storage diseases; evidence of active substance abuse, significant systemic illnesses; contraindications to magnetic resonance imaging, pregnant or trying to become pregnant; or any other condition that, in the investigator's opinion, may affect the patient's competence or compliance in completing the study.
Clinical Research Evaluation of University of California
at San Diego Nonalcoholic Fatty Liver Disease Cohort. All patients underwent a standardized clinical evaluation, detailed history, anthropometric examination, and fasting biochemical tests at the University of California at San Diego (UCSD) NAFLD Research Center. Detailed information from history and anthropometric examination included age, sex, height, weight, body mass index (BMI), and ethnic background; vital signs were collected by a trained clinical investigator. Alcohol consumption was documented in prior clinical visit and confirmed in the research clinic using the Alcohol Use Disorders Identifications Test and the Skinner questionnaire. Other causes of liver diseases and secondary causes of hepatic steatosis, such as steatogenic medications, were ruled out systematically using history and biochemical tests. Biochemical tests included aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, g-glutamyltranspeptidase, total bilirubin, direct bilirubin, albumin, hemoglobin A 1c , fasting glucose, insulin, prothrombin time, international normalized ratio, fasting lipid panel, platelet count, and ferritin.
Histologic Evaluation in University of California at San
Diego Nonalcoholic Fatty Liver Disease Cohort. All liver biopsy for assessment were performed by an experienced liver pathologist who was blinded to the patient's clinical and radiologic data. Histologic scoring was done using the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System. 1 All biopsies were assessed for the following 4 parameters: steatosis was graded 0-3, lobular inflammation was graded 0-3, ballooning was graded 0-2, and fibrosis stage was classified into 5 stages from 0-4. Presence of nonalcoholic steatohepatitis was defined as a pattern that was consistent with steatohepatitis including presence of steatosis, lobular inflammation, and ballooning with or without perisinusoidal fibrosis.
Magnetic Resonance Elastography of University of California at San Diego Nonalcoholic Fatty Liver Disease
Cohort. Magnetic resonance elastography (MRE) was performed at the UCSD MR3T Research Laboratory using the 3-T research scanner (GE Signa EXCITE HDxt, GE Healthcare, Waukesha, WI) with all participants in the supine position. Participants were asked to fast at least 4 hours before the examination. MRE was performed according to previously described methods 2-5 on commercially available software and hardware (Resoundant, Inc, Rochester, MN) and is fully detailed in the Supplementary Material. The radiologists were blinded to clinical data.
A standard 60-Hz shear wave was generated by an acoustic passive driver attached to the body wall anterior to the liver and coupled with an acoustic active driver outside the magnetic resonance examination room. A 2-dimensional motionsensitized gradient-recalled echo MRE pulse sequence synchronized to the shear wave frequency was acquired to obtain 4 noncontiguous axial slices (10-mm thickness, 10-mm interslice gap), each during a 16-second breath-hold, through the widest transverse section of the liver with short recovery times in between. The acquisition parameters were as follows: repetition time, 50 ms; echo time, 20.2 ms; flip angle, 30
; matrix, 256 Â 64; field of view, 48 Â 48 cm; 1-signal average; receiver bandwidth AE 33 kHz; and parallel imaging accelerating factor, 2. The total acquisition time was approximately 2 minutes. The wave images from each slice location were automatically processed on the scanner computer using inversion algorithm to generate axial liver stiffness maps called elastograms. The elastograms were transferred and analyzed offline by a trained image analyst (at least 6 months of experience with MRE analysis) blinded to clinical and histologic data. While avoiding liver edges, large blood vessels, and artifacts, the image analyst drew regions of interests on the elastograms using a custom software package in parts of the liver where wave propagation was shown clearly on the wave images. The mean per-pixel liver stiffness values across regions of interests at the 4 slices were calculated and automatically recorded in an electronic spreadsheet.
The threshold used for the dichotomized classification of liver fibrosis stage 1-4 versus 0, stage 2-4 versus 0-1, stage 3-4 versus 0-2, and stage 4 versus stage 0-3 were 2.65 kPa, 2.86 kPa, 2.99 kPa, and 3.35 kPa, respectively, as previously determined in this cohort. 6 Transient Elastography in University of California at San Diego Nonalcoholic Fatty Liver Disease Cohort. Transient elastography (TE) was performed by a trained technician, blinded to clinical and histologic results, using the FibroScan 502 Touch model (M Probe, XL Probe, Echosens, Paris, France). TE measurement was obtained in the supine position with the right arm fully adducted by scanning the area of abdomen at the location of the right liver lobe during a 10-second breath-hold. Participants were asked to fast at least 3 hours before the examination. The procedure included a minimum of 10 measurements to determine the median valid liver stiffness measurements in kilopascals and the interquartile range. According to the manufacturer protocol, all patients were first scanned using the M probe (3.5 MHz) and when indicated by the equipment on initial assessment, patients were rescanned using the XL probe (2.5 MHz). Technical failure was defined as no stiffness measurement obtained or unreliable measurements (defined as success rate <60% and/or interquartile range/median >30%). 7 The controlled attenuated parameter value in decibel/meter was simultaneously measured for the assessment of liver steatosis measurements, colocalized to the valid liver stiffness measurements.
The threshold used for the dichotomized classification of liver fibrosis stage 1-4 versus 0, stage 2-4 versus 0-1, stage 3-4 versus 0-2, and stage 4 versus stage 0-3 were 6.10 kPa, 6.90 kPa, 7.30 kPa, and 6.90 kPa, respectively, as previously determined in the cohort. 6 
Mayo Clinic Nonalcoholic Fatty Liver Disease Validation Cohort
Inclusion/Exclusion Criteria for the Mayo Clinic Nonalcoholic Fatty Liver Disease Cohort. Participants were included in the study if they were 18 years or older with NAFLD verified with liver histologic examination within at least 48 hours, but no later than 1 month, of study enrollment and were willing and able to provide informed consent.
Participants were excluded if they met any of the following criteria: absolute contraindications to magnetic resonance imaging, including pacemaker, automatic implantable cardioverter-defibrillator device, cochlear implant, ventriculoperitoneal shunt, aneurysm clip, deep brain stimulator, and severe claustrophobia; absolute contraindications to liver biopsy, including coagulopathy and allergy to local anesthetic medication; history of decompensated cirrhosis complicated by 1 or more of esophageal variceal hemorrhage, ascites, hepatic encephalopathy, or spontaneous bacterial peritonitis; women who are pregnant or breastfeeding; history of liver transplantation or hepatic resection; history of primary or secondary hepatic malignancy; current or previous excessive alcohol consumption within 6 months of study enrollment, defined as more than 30 g/day for men and more than 20 g/day for women; history of bariatric surgery more than 1 month before study enrollment; current or previous history of therapy for an underlying liver disease including interferon-based medications, other antiviral agents, immunomodulatory therapy, biologic response modifier therapy, and complementary and/or alternative medications including (but not encompassing) milk thistle; and any severe medical condition that, in the opinion of the principal investigator, would serve as grounds for exclusion from the study.
Histologic Evaluation of Mayo Clinic Cohort. Liver specimens were fixed in formalin, embedded in paraffin, and stained with hematoxylin-eosin and Masson trichrome stains. The Brunt classification was used for histopathologic interpretations where stage F0 represents no fibrosis; F1, perisinusoidal or periportal fibrosis; F2, perisinusoidal and periportal fibrosis; F3, bridging fibrosis; and F4, cirrhosis. 8 The grade of necroinflammatory activity for all histologic liver specimens was evaluated semiquantitatively on a scale of A0 to A3 according to location as either portal or lobular. 8 A group of staff hepatopathologists performed the first interpretation of the liver biopsy specimens as part of the clinical service, and 1 independent hepatopathologist provided a second interpretation while blinded to the results of the first interpretation and elastography. For discrepancies in fibrosis stage, the independent hepatopathologist reviewed the cases again and provided a final interpretation. In addition, the length of the liver biopsy sample (in millimeters), the number of portal tracts in the biopsy sample, and biopsy type were recorded. The final interpretations from the independent hepatopathologist were used for the statistical analysis.
Magnetic Resonance Elastography of Mayo Clinic Nonalcoholic Fatty Liver Disease Cohort. MRE uses a pneumatic driver system to send mechanical shear waves into the patient's liver and uses magnetic resonance imaging to produce images of wave propagation in the liver that are processed to create cross-sectional maps of liver stiffness (shear modulus, in kilopascals). [9] [10] [11] In the study, patients underwent MRE in the supine position, with a 19-cmdiameter passive drum driver placed against the anterior body wall close to the right hepatic lobe. The passive driver was secured with an elastic belt wrapped around the body and connected to an MRE active driver system via a 7.6-m-long flexible vinyl chloride tube with an inside diameter of 1.9 cm. A 1.5-T whole-body magnetic resonance imaging unit with a 60-cm bore (Signa, GE Medical Systems, Milwaukee, WI) was used with an 8-channel torso radiofrequency coil array.
Wave images were processed on the imager automatically by the proprietary multimodel direct inversion algorithm (Mayo Clinic, Rochester, MN), producing 4 sections showing the stiffness distribution in the liver (elastograms) and associated wave confidence maps. The confidence maps report the correlation coefficient of local polynomial fits to the wave images and reflect the wave image signal-to-noise ratio (including wave amplitude and magnetization signal-to-noise ratio) and the presence of artifacts (eg, blood vessels). Two readers (M.Y. and J.C., with 11 and 7 years of experience, respectively) drew regions of interest inside the hepatic parenchyma, about 5-10 pixels away from the liver boundary, excluding regions with major blood vessels and wave confidence below 95%. The readers were blinded to the clinical history and results of liver biopsy. The mean and standard deviation of liver stiffness in the regions of interest were reported. Patients also underwent in-phase and out-of-phase hepatic fat imaging with the parameters described previously.
The MRE parameters were as follows: flowcompensated gradient-echo MRE sequence; axial imaging plane; 32-to 44-cm field of view; 256 Â 64 acquisition matrix; 30 flip angle; 4 contiguous sections of 10 m prescribed through the widest portion of the liver and imaged sequentially; repetition time ms/echo time ms ¼ 50/20.2 ms; 60-Hz driver frequency; 16.7-ms through-plane motion sensitizing gradient; motion sensitizing gradient sensitivity ¼ 10.1 mm per radian; 4 time offset; bandwidth of AE 31.25 kHz; and imaging time ¼ 54 seconds split into 4 breath-holds performed at the end of expiration. The in-phase and out-of-phase hepatic fat imaging included the following parameters: fast gradientecho sequence; axial images; 32-to 44-cm field of view; 256 Â 128 acquisition matrix; 70 flip angle; 24 sections of 6 mm; repetition time ms/echo time 1 ms/echo time 2 ms ¼ 100.0/2.13/4.94; receiver bandwidth of AE 50 kHz; imaging time ¼ 22 seconds split into 2 breath-holds performed at the end of expiration. Regions of interest were drawn by 1 of the authors (J.C.) in the 4 sections closest to the location of the MRE sections, including only liver parenchyma and excluding blood vessels. Fat content was calculated as (IP À OP)/(2 Â IP), where IP is the signal intensity of the in-phase images and OP is the signal intensity of the out-of-phase images. 12 The threshold used for the dichotomized classification of liver fibrosis stage 1-4 versus 0, stage 2-4 versus 0-1, stage 3-4 versus 0-2, and stage 4 versus stage 0-3 were 2.60 kPa, 3.50 kPa, 3.60 kPa, and 4.52 kPa, respectively, as previously determined in the cohort. 13 
Transient Elastography of Mayo Clinic Nonalcoholic
Fatty Liver Disease Cohort. Patients underwent vibration controlled transient elastography (VCTE) (Fibroscan, Echosens) to measure liver stiffness (Young modulus, in kilopascals) on the same day as MRE with use of a standard M probe or an XL probe that is designed for patients with a high BMI. The M probe and XL probe have different central ultrasound frequencies (3.5 MHz vs 2.5 MHz) and measurement depths (2.5-6.5 cm vs 3.5-7.5 cm). VCTE was performed with the patient in the supine position with the right arm in maximal abduction. The operators used a portable ultrasound scanner (Vscan, GE Medical Systems) in the abdominal mode to identify a spot on the chest between the ribs at the level of the right hepatic lobe where the subcutaneous fat was thin and the liver was free of large vascular structures. The skin-to-capsule distance (SCD) was measured first with the portable ultrasound scanner. Then the operators positioned 1 of the 2 VCTE probes (M or XL) on the designated intercostal spot with appropriate pressure and launched the VCTE measurements. The M probe was chosen for patients with SCD of 2.5 cm or less, and the XL probe was used for patients with SCD of more than 2.5 cm. If the M probe failed, however, the XL probe was used even if SCD was less than 2.5 cm. The VCTE examination consists of performing repeated measurements of the liver stiffness, with each measurement assessed as valid (a white wave front line shows up) or invalid (no white wave front line shows up) automatically by the VCTE system. When a VCTE operator started an examination, the goal was to have at least 10 valid measurements; if there were fewer than 10 valid measurements, more measurements were launched for approaching the goal. Three manufacture-certified operators, all with 3 years of experience, performed the VCTE examinations. At least 2 of the 3 operators were in the examination room for each patient. The first operator tried to get at least 10 valid measurements; if that failed, then the second operator started over with a new examination and tried to complete the examination until 10 valid measurements were achieved. After multiple trials, if both operators agreed that achieving 10 valid measurements (total attempted measurements could be more than 10) were not possible, then the examination was recorded as a technique failure (<10 valid measurements).
The median value of the 10 valid measurements was recorded as the patient liver stiffness. In addition, the interquartile range of the valid measurements and the valid measurement rate (the number of valid measurements divided by the number of attempted measurements) of the examination were recorded. For our study, we applied the most commonly used reliability criteria for VCTE proposed by Castera et al 14 : a set of stiffness values are considered reliable if at least 60% of the individual measurements are reported as valid by the instrument and the interquartile range/median ratio is 30% or less. The total examination time was about 5-15 minutes.
The threshold used for the dichotomized classification of liver fibrosis stage 1-4 versus 0, stage 2-4 versus 0-1, stage 3-4 versus 0-2, and stage 4 versus stage 0-3 were 6.30 kPa, 7.80 kPa, 7.60 kPa, and 14.60 kPa, respectively, as previously determined in this cohort. 13 
Supplementary Results
Diagnostic Performance of Magnetic Resonance Elastography and Transient Elastography Stratified by Body
